Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus
Starpharma’s (SPL) antiviral agent achieves up to 99.7 per cent reduction in…
Change | ||
S&P/ASX Sm. Ords. | |||
All Ordinaries | |||
S&P/ASX 100 |
OKU | OKLO RESOURCES LIMITED | 14.5¢ | 90.8% |
IVO | INVIGOR GROUP LIMITED | 5.5¢ | 57.1% |
LIN | LINDIAN RESOURCES LIMITED | 5.5¢ | 41.0% |
FDR | FINDER ENERGY HOLDINGS LIMITED | 11.0¢ | 40.5% |
APX | APPEN LIMITED | $6.54 | 20.9% |
PRX | PRODIGY GOLD NL | 1.9¢ | 17.4% |
Date | Announcement | File | Views |
---|---|---|---|
27/05/2022 | Notification of cessation of securities - SPL | 21.51KB | 317 |
27/05/2022 | Application for quotation of securities - SPL | 26.57KB | 1.1K |
18/05/2022 | Price Sensitive PS SPL7013 in VIRALEZE virucidal against influenza A and B | 281.77KB | 5.6K |
29/04/2022 | Price Sensitive PS Quarterly Cashflow and Activities Report | 357.52KB | 7.7K |
28/04/2022 | Change in substantial holding | 170.7KB | 9.4K |
27/04/2022 | Starpharma to present DEP at Boston ADC summit | 224.42KB | 3.3K |
01/04/2022 | Dr Jeff Davies appointed as director and Appendix 3X | 381.89KB | 4.4K |
01/04/2022 | Price Sensitive PS VIRALEZE to relaunch in the UK | 257.72KB | 20K |